Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
1.350
-0.030 (-2.17%)
At close: Sep 12, 2025, 4:00 PM EDT
1.370
+0.020 (1.47%)
After-hours: Sep 12, 2025, 7:53 PM EDT
Senti Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
35.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
Dec 31, 2020 | 566.00K | 481.00K | 565.88% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SNTI News
- 11 days ago - Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 4 weeks ago - Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia - GlobeNewsWire
- 5 weeks ago - Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - GlobeNewsWire
- 5 weeks ago - Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia - GlobeNewsWire
- 7 weeks ago - Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
- 7 weeks ago - Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum - GlobeNewsWire
- 2 months ago - Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors - GlobeNewsWire